Fate Therapeutics CEO J. Scott Wolchko retires; Bahram Valamehr appointed successor; advisory agreement signed

FATE THERAPEUTICS INC

J. Scott Wolchko retired as President, CEO, and CFO effective Dec 31, 2024; resignation not due to any policy disagreement.
Bahram Valamehr, Ph.D., MBA succeeded as President, CEO, and subsidiary roles effective Jan 1, 2025.
Wolchko entered 12-month advisory agreement with $56,250 monthly cash compensation and continued equity vesting through Dec 31, 2025.
Wolchko's vested options may be exercised until Dec 31, 2026; equity awards accelerate if agreement terminated early by company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bahram Valamehr

President and Chief Executive Officer

FATE · FATE THERAPEUTICS INC

Effective: 2025-01-01
Filed: January 6, 2025, 6:59 PM ET

Bahram Valamehr, Ph.D., MBA has succeeded Mr. Wolchko in each of the Subsidiary Roles, effective as of January 1, 2025.

Departed

J. Scott Wolchko

President, Chief Executive Officer, Chief Financial Officer

FATE · FATE THERAPEUTICS INC

Effective: 2024-12-31
Successor: Bahram Valamehr
Filed: January 6, 2025, 6:59 PM ET

J. Scott Wolchko retired from his positions as President, Chief Executive Officer (“CEO”), Chief Financial Officer, Treasurer, principal executive officer, principal financial officer and principal accounting officer of the Company, effective as of December 31, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bahram Valamehr was appointed as President and Chief Executive Officer at FATE THERAPEUTICS INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Bahram Valamehr, Ph.D., MBA has succeeded Mr. Wolchko in each of the Subsidiary Roles, effective as of January 1, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

J. Scott Wolchko retired as President, Chief Executive Officer, Chief Financial Officer at FATE THERAPEUTICS INC.

Action: retired
Role: President, Chief Executive Officer, Chief Financial Officer

Exact text from the filing

J. Scott Wolchko retired from his positions as President, Chief Executive Officer (“CEO”), Chief Financial Officer, Treasurer, principal executive officer, principal financial officer and principal accounting officer of the Company, effective as of December 31, 2024

View on SEC.gov

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-002153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.